Dm Disease-A-Month最新文献

Myasthenia gravis (MG) is an autoimmune neuromuscular disorder characterized by muscle weakness and fatiguability. The pathogenesis of MG is mediated in most cases by autoantibodies directed against the nicotinic acetylcholine receptor at the neuromuscular junction, although less commonly autoantibodies may target muscle-specific kinase (MuSK) or low-density lipoprotein receptor-related protein 4 (LRP4). These autoantibodies disrupt cholinergic transmission at the neuromuscular junction through several mechanisms, including direct functional blocking, downregulation, destruction, or disruption of receptor clustering in the postsynaptic membrane. MG is characterized by fatigable muscle weakness in the ocular, bulbar, respiratory or limb muscles. Clinical manifestations can vary significantly among individuals depending on the type of autoantibody or presence of thymoma. Due to the variable presentation of symptoms, diagnosing MG can be challenging. A comprehensive approach that combines clinical assessment, serological testing, electrophysiological studies, and imaging is essential for accurate diagnosis.

To better understand what it's like to live with Lambert-Eaton myasthenic syndrome (LEMS), we spoke to two individuals who have been living with non-tumor LEMS for years. They graciously shared stories that shed light on the day to day impact of this rare condition extending from mobility and daily functioning to identity, relationships, and mental health. In sharing their experiences, they also offered insights and advice for others newly diagnosed with LEMS or managing its challenges long-term.

To better understand what it's like to live with myasthenia gravis (MG), we spoke to two individuals who have been living with the disease for years. They graciously shared stories that shed light on the day to day impact of this rare condition extending from muscle strength and daily functioning to personal identity and relationships. In sharing their experiences, they also offered insights and advice for others newly diagnosed with MG and for physicians managing the patients and their challenges.

The neuromuscular junction (NMJ) is highly susceptible to neurotoxins due to its lack of protective barriers like the blood-brain barrier. Over time, a wide range of natural toxins have evolved to target the NMJ, derived from animals, plants, and bacteria, alongside modern synthetic compounds developed for use in medicine, insecticides, and warfare. These toxins exert their effects through various mechanisms, such as antagonizing or agonizing nicotinic and muscarinic acetylcholine receptors, or inhibiting neurotransmitter release or breakdown. Despite their diverse origins and actions, NMJ toxins often present clinically with muscle weakness and can lead to respiratory failure if untreated. However, variations in presentation and clinical context are critical for accurate diagnosis and appropriate treatment. Understanding these mechanisms is essential for early recognition, effective management, informed use of current medications, and the development of novel therapeutics.

The challenge of treating of Myasthenia Gravis (MG) stems from the multiple underlying mechanisms, the varied presentations, the need for chronic immunotherapy, and the long-term consequences of treatment. The disease itself is varied with clinical presentations ranging from droopy eyes to respiratory failure. The underlying etiology may be paraneoplastic or one of several identified antibodies that affect the post-synaptic neuromuscular junction. Treatment strategies vary depending on all of these factors. There are limited medications available for symptomatic treatment of the neuromuscular junction while most treatment focuses on immunotherapy to limit the immune response. Thymectomy is beneficial for most patients with thymoma and many with antibody positive disease. Choosing the right treatments to maximize benefits and limit adverse effects of the medicines is crucial in this chronic disease.